| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
COGNITION THERAPEUTICS INC (NASDAQ: CGTX)
CGTX Technical Analysis
2
| As on 9th Jun 2023 CGTX STOCK Price closed @ 2.77 and we RECOMMEND Buy for LONG-TERM with Stoploss of 2.76 & Strong Sell for SHORT-TERM with Stoploss of 4.49 we also expect STOCK to react on Following IMPORTANT LEVELS. |
CGTXSTOCK Price
| Open | 2.95 | Change | Price | % |
| High | 3.16 | 1 Day | -0.23 | -7.67 |
| Low | 2.75 | 1 Week | 0.72 | 35.12 |
| Close | 2.77 | 1 Month | 1.06 | 61.99 |
| Volume | 52689 | 1 Year | -2.70 | -49.36 |
| 52 Week High 6.90 | 52 Week Low 1.17 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| CGTX Daily Charts |
CGTX Intraday Charts |
Whats New @ Bazaartrend |
CGTX Free Analysis |
|
|
CGTX Important Levels Intraday
| RESISTANCE | 3.56 |
| RESISTANCE | 3.31 |
| RESISTANCE | 3.15 |
| RESISTANCE | 2.99 |
| SUPPORT | 2.55 |
| SUPPORT | 2.39 |
| SUPPORT | 2.23 |
| SUPPORT | 1.98 |
CGTX Forecast April 2024
| 4th UP Forecast | 10.82 |
| 3rd UP Forecast | 8.24 |
| 2nd UP Forecast | 6.64 |
| 1st UP Forecast | 5.05 |
| 1st DOWN Forecast | 0.49 |
| 2nd DOWN Forecast | -1.1 |
| 3rd DOWN Forecast | -2.7 |
| 4th DOWN Forecast | -5.28 |
CGTX Weekly Forecast
| 4th UP Forecast | 6.14 |
| 3rd UP Forecast | 5.06 |
| 2nd UP Forecast | 4.39 |
| 1st UP Forecast | 3.72 |
| 1st DOWN Forecast | 1.82 |
| 2nd DOWN Forecast | 1.15 |
| 3rd DOWN Forecast | 0.48 |
| 4th DOWN Forecast | -0.60 |
CGTX Forecast2024
| 4th UP Forecast | 14.78 |
| 3rd UP Forecast | 10.93 |
| 2nd UP Forecast | 8.55 |
| 1st UP Forecast | 6.17 |
| 1st DOWN Forecast | -0.63 |
| 2nd DOWN Forecast | -3.01 |
| 3rd DOWN Forecast | -5.39 |
| 4th DOWN Forecast | -9.24 |
COGNITION THERAPEUTICS INC ( NASDAQ USA Symbol : CGTX )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
CGTX Business Profile
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in phase 2 clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed phase 1 clinical trial to treat early-stage Alzheimer's disease; and in preclinical trial to treat dementia with Lewy bodies (DLB) and dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York. Address:
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service